Unixell Biotechnology obtained FDA IND clearance for UX-DA003, its allogeneic iPSC-derived therapy for Parkinson’s disease, enabling clinical development in the U.S. The company also reported IND clearance in China earlier this month, supporting parallel development plans across both markets.